Exonate fundraises £1.5 million
Exonate has successfully fundraised £1.5 million to accelerate development of its lead product – an eye drop treatment for retinal neovascular diseases.
Read More
Tag: retinal neovascular diseases
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
